Advertisement
Canada markets open in 3 hours 13 minutes

  • S&P/TSX

    21,871.96
    +64.59 (+0.30%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CAD/USD

    0.7296
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    81.95
    +0.05 (+0.06%)
     

  • Bitcoin CAD

    90,672.61
    +154.90 (+0.17%)
     

  • CMC Crypto 200

    1,420.03
    +5.27 (+0.37%)
     

  • GOLD FUTURES

    2,313.40
    -33.00 (-1.41%)
     

  • RUSSELL 2000

    1,967.47
    +19.82 (+1.02%)
     

  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     

  • NASDAQ futures

    17,371.75
    +21.75 (+0.13%)
     

  • VOLATILITY

    16.73
    -0.21 (-1.24%)
     

  • FTSE

    8,052.36
    +28.49 (+0.36%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6841
    -0.0009 (-0.13%)
     

Akouos to Present at 20th Annual Needham Virtual Healthcare Conference

Akouos, Inc.
·1 min read

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., founder, president, and CEO of Akouos, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14 at 4:30 p.m. ET.

A live webcast of the fireside chat will be available on the investors section of the company’s website at www.akouos.com. To access the webcast, please go on to the Akouos website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Akouos’s website for 14 days following the conference.

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

Contacts

Media:
Katie Engleman, 1AB
katie@1abmedia.com

Investors:
Courtney Turiano, Stern Investor Relations
Courtney.Turiano@sternir.com